Table 3.
Utilities
| Parameter | Estimate | Range * | Duration (months) | Source |
|---|---|---|---|---|
| Hysterectomy for fibroidsa | 0.9 | [0.72, 1.0] | 6 | O'Sullivan40 |
| Transfusion | 0.48 | [0.38, 0.58] | 1 | Klarenbock41 |
| Wound infection | 0.607 | [0.49, 0.73] | 1 | Chatterjee42 |
| Vaginal cuff dehiscence | 0.54 | [0.43, 0.65] | 1 | Chatterjee42 |
| Venous thromboembolism | 0.8 | [0.64, 0.96] | 12 | Spangler43 |
| Hernia | 0.77 | [0.62, 0.92] | 24 | Hynes44 |
| Leiomyosarcoma (1st 6 months chemotherapy) b | 0.76 | [0.61, 0.91] | 6 | Reichardt45 |
| Leiomyosarcoma progression (additional 12-months chemotherapy) c | 0.66 | [0.53, 0.79] | 12 | Reichardt45 |
| Leiomyosarcoma progression (palliative care) d | 0.71 | [0.57, 0.85] | 36 | Health Quality Ontario46 |
| Alive | 1.0 | Not varied | Varies |
*
Range based on +/− 20% of base-case utility. If +20% exceeded 1.0, the utility was assigned a value of 1.0
a
Decrement applied only to abdominal hysterectomy
b
For women with leiomyosarcoma diagnosed at time of surgery, we presumed all would receive a minimum 6 months of chemotherapy (approximately 6 cycles). Responders would get no more treatment and return to normal health.
c
Non-responders after 6 months would get additional chemotherapy (up to 12 months).
d
Non-responders after 12 months of chemotherapy would go on to palliative care and ultimately die of their disease